Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival

被引:106
|
作者
Koukourakis, MI [1 ]
Giatromanolaki, A
Kakolyris, S
O'Byrne, KJ
Apostolikas, N
Skarlatos, J
Gatter, KC
Harris, AL
机构
[1] Univ Hosp Irakl, Dept Radiotherapy Oncol, Iraklion 71110, Greece
[2] Univ Hosp Irakl, St Nikolas Histopathol Unit, Iraklion 71110, Greece
[3] Oxford Radcliffe Hosp, Dept Cellular Sci, Oxford OX3 7LJ, England
[4] Oxford Radcliffe Hosp, Dept ICRF, Med Oncol Unit, Oxford OX3 7LJ, England
[5] Hellen Canc Inst, Dept Radiat Oncol, Athens, Greece
[6] Hellen Canc Inst, Dept Histopathol, Athens, Greece
关键词
PD-ECGF; thymidine phosphorylase fibroblast; macrophage; lung cancer;
D O I
10.1038/bjc.1998.280
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is recognized as an important step in tumour pathogenesis that is related to invasion and metastatic spread and which consequently results in poor clinical outcome. In this study, we have examined the role of tumour stroma-activated fibroblasts and macrophage infiltration in the development of the angiogenic and metastatic phenotype in non-small-cell lung cancer (NSCLC). A total of 141 cases of early stage I-Il NSCLC treated with surgery alone were analysed. The JC-70 (anti-CD31) MAb was used for the assessment of vascular grade. The P-GF.44C MAb was used to assess thymidine phosphorylase (TP) reactivity in cancer cells, stromal fibroblasts and macrophages, Cancer cell TP overexpression related to high vascular grade and to advanced T stage (P = 0.0004 and P = 0.02). Expression of TP in stromal fibroblasts also correlated with high angiogenesis (P = 0.01), but was independent of cancer cell expression. Fibroblast TP overexpression was related to abundant stroma (P=0.003), suggesting that TP may be a marker of active stroma, Moreover, intense macrophage infiltration was associated with fibroblast TP reactivity, regardless of the amount of stroma, suggesting that macrophages may be a major contributor to TP expression in stroma. Survival analysis showed that cancer cell TP overexpression was related to poor prognosis (P = 0.005). Although stroma TP is related to angiogenesis, in the low vascular grade group it defined a group of patients with better prognosis (P = 0.02). It may be that fibroblast TP reactivity is an indirect marker of tumour infiltration by functional macrophages, which have an anti-tumour effect, We conclude that stromal macrophage and fibroblast TP reactivity may have an important role in non-small-cell lung cancer behaviour. Understanding the role of stromal fibroblasts and inflammatory cells and their interaction with oncoprotein expression is essential for the elucidation of lung cancer pathogenesis.
引用
收藏
页码:1696 / 1703
页数:8
相关论文
共 50 条
  • [31] Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency
    Kumar, Prashanth Ashok
    Graziano, Stephen L.
    Danziger, Natalie
    Pavlick, Dean
    Severson, Eric A.
    Ramkissoon, Shakti H.
    Huang, Richard S. P.
    Decker, Brennan
    Ross, Jeffrey S.
    CANCER MEDICINE, 2023, 12 (02): : 1157 - 1166
  • [32] Diagnostic patterns of non-small-cell lung cancer at Princess Margaret Cancer Centre
    Nadjafi, M.
    Sung, M. R.
    Santos, G. D. C.
    Le, L. W.
    Hwang, D. M.
    Tsao, M. S.
    Leighl, N. B.
    CURRENT ONCOLOGY, 2020, 27 (05) : 243 - 249
  • [33] Advanced Non-Small-Cell Lung Cancer
    Kwon, Hyun W.
    Ham, Soo-Youn
    Shin, Sang W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1997 - +
  • [34] Pembrolizumab in Non-Small-Cell Lung Cancer
    Sorscher, Steven
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (10): : 996 - 997
  • [35] Encephalitis in non-small-cell lung cancer
    Costa e Silva, M.
    Silva, E.
    Mendes, A.
    Barroso, A.
    PULMONOLOGY, 2021, 27 (06): : 582 - 583
  • [36] Immunotherapy of non-small-cell lung cancer
    Reinmuth, Niels
    Merk, Martina
    Duell, Thomas
    ONKOLOGE, 2021, 27 (02): : 179 - 190
  • [37] Avelumab in non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET ONCOLOGY, 2018, 19 (11): : 1423 - 1424
  • [38] Radiochemotherapy in non-small-cell lung cancer
    Swartman, B.
    Hausmanns, J.
    Zwicker, F.
    Thomas, M.
    Herfarth, K.
    Heussel, C. P.
    MEDIZINISCHE KLINIK, 2011, 106 (03) : 212 - 217
  • [39] Cetuximab in non-small-cell lung cancer
    Carillio, Guido
    Montanino, Agnese
    Costanzo, Raffaele
    Sandomenico, Claudia
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Daniele, Gennaro
    Giordano, Pasqualina
    Bryce, Jane
    Normanno, Nicola
    Rocco, Gaetano
    Perrone, Francesco
    Morabito, Alessandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (02) : 163 - 175
  • [40] Non-small-cell lung cancer in the elderly
    Meriggi, F
    Zaniboni, A
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 57 (02) : 183 - 190